{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%2B+ADT", "query": { "intervention": "Placebo + ADT" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 66, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%2B+ADT&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T07:35:06.206Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04493853", "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Abiraterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1012, "start_date": "2020-07-13", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 33, "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493853" }, { "nct_id": "NCT00181584", "title": "Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Loss", "Prostate Cancer" ], "interventions": [ { "name": "Zoledronic acid", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2003-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-11", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00181584" }, { "nct_id": "NCT04455750", "title": "A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Rucaparib camsylate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 61, "start_date": "2021-10-14", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 414, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04455750" }, { "nct_id": "NCT02064946", "title": "High-dose Vitamin D Supplementation for ADT-induced Side Effects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostatic Neoplasms", "Bone Mineral Density Quantitative Trait Locus 3" ], "interventions": [ { "name": "vitamin D", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "60 Years to 99 Years · Male only" }, "enrollment_count": 108, "start_date": "2014-03", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2019-04-08", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02064946" }, { "nct_id": "NCT05348577", "title": "Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "capivasertib", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1035, "start_date": "2022-03-25", "completion_date": "2026-03-04", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 37, "location_summary": "Yuma, Arizona • Beverly Hills, California • Cerritos, California + 31 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05348577" }, { "nct_id": "NCT06846320", "title": "Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Anxiety Disorder (GAD)" ], "interventions": [ { "name": "ABBV-932", "type": "DRUG" }, { "name": "Placebo for ABBV-932", "type": "DRUG" }, { "name": "Antidepressant Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 315, "start_date": "2025-04-29", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 49, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846320" }, { "nct_id": "NCT02677896", "title": "A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Hormone Sensitive Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1150, "start_date": "2016-03-09", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 34, "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677896" }, { "nct_id": "NCT02489318", "title": "A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aragon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1052, "start_date": "2015-11-27", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 39, "location_summary": "Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Bernardino", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489318" }, { "nct_id": "NCT01727726", "title": "A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder", "Depression", "Depressive Disorder, Major", "Mood Disorders", "Mental Disorders" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Seroquel XR", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2182, "start_date": "2012-12", "completion_date": "2016-11-10", "has_results": true, "last_update_posted_date": "2018-06-08", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01727726" }, { "nct_id": "NCT01214291", "title": "Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Risk of Bone Fracture Occurrences" ], "interventions": [ { "name": "Toremifene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GTx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "MALE", "summary": "50 Years to 80 Years · Male only" }, "enrollment_count": 0, "start_date": "2011-03", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2013-11-15", "last_synced_at": "2026-09-10T07:35:06.206Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01214291" } ] }